HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-Charles Soria Selected Research

human TNFSF10 protein

11/2011Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
3/2010Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-Charles Soria Research Topics

Disease

240Neoplasms (Cancer)
07/2022 - 05/2002
117Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 05/2002
53Lung Neoplasms (Lung Cancer)
01/2022 - 01/2003
18Disease Progression
01/2020 - 10/2006
17Neoplasm Metastasis (Metastasis)
12/2018 - 05/2003
14Fatigue
01/2021 - 02/2013
14Breast Neoplasms (Breast Cancer)
01/2020 - 12/2004
13Adenocarcinoma
02/2021 - 07/2004
13Adenocarcinoma of Lung
01/2020 - 03/2005
13Nausea
01/2020 - 02/2013
13Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2018 - 07/2004
10Carcinoma (Carcinomatosis)
10/2018 - 01/2002
10Carcinogenesis
09/2011 - 01/2002
9Melanoma (Melanoma, Malignant)
10/2019 - 08/2010
8Diarrhea
01/2020 - 10/2006
8Vomiting
01/2020 - 03/2013
7Exanthema (Rash)
01/2021 - 10/2006
7Renal Cell Carcinoma (Grawitz Tumor)
01/2019 - 06/2010
7Thrombocytopenia (Thrombopenia)
10/2018 - 03/2010
6COVID-19
01/2022 - 01/2020
6Circulating Neoplastic Cells
01/2020 - 01/2002
6Sarcoma (Soft Tissue Sarcoma)
01/2020 - 02/2010
6Neutropenia
05/2017 - 03/2008
6Colorectal Neoplasms (Colorectal Cancer)
08/2014 - 10/2003
5Pneumonia (Pneumonitis)
11/2021 - 09/2009
5Prostatic Neoplasms (Prostate Cancer)
01/2020 - 10/2010
4Lymphopenia (Lymphocytopenia)
12/2021 - 01/2016
4Anorexia
10/2018 - 02/2013
4Lymphoma (Lymphomas)
01/2018 - 05/2012
4Cardiotoxicity
07/2016 - 04/2007
4Stomatitis
01/2016 - 10/2013
4Necrosis
01/2016 - 01/2011
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/2013 - 08/2003
3Urinary Bladder Neoplasms (Bladder Cancer)
01/2022 - 01/2002
3Genomic Instability
11/2021 - 05/2008
3Mesothelioma
11/2020 - 09/2009
3Glioblastoma (Glioblastoma Multiforme)
01/2020 - 06/2015
3Leukemia
01/2019 - 03/2013

Drug/Important Bio-Agent (IBA)

47Biomarkers (Surrogate Marker)IBA
01/2022 - 11/2004
26Cisplatin (Platino)FDA LinkGeneric
01/2019 - 09/2006
25Proteins (Proteins, Gene)FDA Link
01/2022 - 09/2004
24Pharmaceutical PreparationsIBA
01/2022 - 07/2004
21Tyrosine Kinase InhibitorsIBA
07/2022 - 01/2005
19Immune Checkpoint InhibitorsIBA
01/2022 - 02/2014
18ErbB Receptors (EGF Receptor)IBA
11/2018 - 11/2003
17PlatinumIBA
01/2021 - 07/2007
15Biological ProductsIBA
01/2018 - 12/2003
14DNA (Deoxyribonucleic Acid)IBA
01/2022 - 10/2003
14Monoclonal AntibodiesIBA
10/2019 - 01/2006
14Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2018 - 10/2006
13Bevacizumab (Avastin)FDA Link
11/2017 - 02/2010
10Paclitaxel (Taxol)FDA LinkGeneric
11/2017 - 02/2006
9pembrolizumabIBA
07/2022 - 05/2015
9Phosphotransferases (Kinase)IBA
10/2021 - 07/2005
9Carboplatin (JM8)FDA LinkGeneric
10/2021 - 02/2006
9LigandsIBA
01/2019 - 11/2005
9CrizotinibIBA
04/2017 - 05/2012
9Telomerase (Telomerase Reverse Transcriptase)IBA
06/2010 - 01/2002
8AntibodiesIBA
01/2022 - 05/2015
8GemcitabineFDA Link
06/2017 - 07/2007
8Sorafenib (BAY 43-9006)FDA Link
01/2017 - 08/2009
7Gefitinib (Iressa)FDA Link
01/2020 - 02/2006
7Pemetrexed (MTA)FDA Link
11/2017 - 04/2009
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2017 - 12/2009
6EverolimusFDA Link
04/2021 - 12/2010
6Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2021 - 03/2013
6Anaplastic Lymphoma KinaseIBA
01/2020 - 11/2016
6AfatinibIBA
09/2019 - 08/2015
6Messenger RNA (mRNA)IBA
09/2013 - 09/2002
5B7-H1 AntigenIBA
01/2022 - 11/2014
5RNA (Ribonucleic Acid)IBA
12/2021 - 05/2007
5ParaffinIBA
01/2019 - 09/2011
5Cyclin-Dependent Kinases (cdk Proteins)IBA
06/2017 - 05/2010
5Alanine Transaminase (SGPT)IBA
05/2017 - 11/2016
5EnzymesIBA
02/2013 - 07/2006
4NivolumabIBA
01/2022 - 01/2017
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2020 - 09/2012
4Formaldehyde (Formol)FDA Link
01/2019 - 09/2013
4Vinorelbine (Navelbine)FDA LinkGeneric
01/2019 - 01/2016
4AlbuminsIBA
01/2018 - 03/2012
4atezolizumabIBA
01/2018 - 11/2014
4Angiogenesis InhibitorsIBA
08/2014 - 04/2009
4Trastuzumab (Herceptin)FDA Link
01/2014 - 12/2010
3Immunologic Factors (Immunomodulators)IBA
07/2022 - 06/2013
3Immunoconjugates (Immunoconjugate)IBA
01/2022 - 01/2019
3durvalumabIBA
01/2022 - 01/2016
3Antiviral Agents (Antivirals)IBA
01/2022 - 05/2016
3CytokinesIBA
01/2022 - 01/2011
3InterferonsIBA
01/2022 - 01/2011
3osimertinibIBA
01/2020 - 11/2018
3Circulating Tumor DNAIBA
01/2019 - 01/2016
3rociletinibIBA
11/2018 - 04/2015

Therapy/Procedure

92Therapeutics
07/2022 - 11/2003
57Drug Therapy (Chemotherapy)
01/2022 - 03/2003
39Immunotherapy
07/2022 - 02/2011
19Adjuvant Chemotherapy
02/2021 - 01/2004
12Precision Medicine
01/2022 - 01/2011
11Radiotherapy
11/2020 - 10/2004
8Chemoprevention
05/2007 - 01/2002
5Molecular Targeted Therapy
01/2016 - 12/2003